GROSS LAW FIRM

Heron Therapeutics, Inc. Loss Submission Form

The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Southern District of California on behalf of shareholders of Heron Therapeutics, Inc. who purchased securities between October 31, 2018 and April 30, 2019.

(i) Heron had failed to include adequate Chemistry, Manufacturing, and Controls (“CMC”) and non-clinical information in its NDA for HTX-011; (ii) the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and (iii) as a result, Heron’s public statements were materially false and misleading at all relevant times.

Heron Therapeutics, Inc.

“Heron Therapeutics, Inc.”

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until August 5, 2019 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

Name

Email

Physical Address

Phone Number

Number of Shares Purchased

Purchase Date

Loss

By submitting your information, it does not create an attorney-client relationship and you are giving us your express consent to contact you by email, text message, SMS, or call you by telephone.

Privacy Notice